Next Phase Newsletter

A venture capital founded in 2006 and based in USA, makes equity investments of up to $4 million into companies over the lifetime of the investment in both the seed and venture stage. The firm is most interested in companies located in California especially for seed stage deals, but will consider investments throughout the United States. The firm is actively seeking new investment opportunities.

The firm is looking for companies in the Medical Device space. The firm is looking for companies in all stages of development and across areas of medicine including cardiovascular and general surgery, orthopedic surgery, cardiology, radiology, oncology, obesity, gynecology, sleep disorders and more including orphan indications.

The firm is looking for companies with experienced management teams though the management team need not be complete. The firm is able to provide assistance in filling gaps in these teams through the firm’s connections in the industry. The firm looks to take a board seat into companies following investment

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm is the corporate venture arm of a Japan-based global pharmaceutical company. The firm seeks to make strategic investments into early-stage companies that are aligned with the parent company’s R&D focus. For equity investments, the firm will lead, co-lead, or participate in syndicated financings. With deep connections into the parent company’s global research and development centers, the firm is ideally placed to nurture innovative pharmaceutical companies and to connect these into the parent organization.

The firm’s core focus is on therapeutics. Currently, the firm is most interested in oncology, gastrointestinal diseases, neuroscience and rare disease. The firm is also interested in breakthrough platforms technologies that improve peptide, antibody, cell, and gene based therapies. The firm does not invest in medical devices or diagnostics.

The firm’s primary focus is on start-up/seed rounds, through mid-stage financings – pre-clinical through Phase II. The firm respects the autonomy of the institutions it invests in and seeks standard institutional venture investment terms without special rights or options.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a global HealthTech and Life Sciences investment fund based in the Middle East. With approximately $1.3 billion AUM, the firm partners with outstanding entrepreneurs who harness groundbreaking science and technology to transform healthcare. Together with their portfolio companies, they work tirelessly to advance solutions that will help people live healthier, better lives. Multidisciplinary by nature, the team has been purpose-built to invest in the HealthTech and life sciences arena. The multidisciplinary team is composed of scientists, physicians, engineers, entrepreneurs, and investors with global experience who are dedicated to science, medicine, and technology. When they partner with a company, they bring the power of their platform to assist management teams and support them as they execute their plans. Through their early stage fund, they invest in companies pursuing disruptive, cutting-edge technologies as early as sponsored research at top academic and clinical institutions to venture formation through seed investments and A rounds. The fund’s initial investments are typically in the range of $0.1-5 million, depending on the stage of the company, with significant amounts reserved for follow on investments in well performing portfolio companies. The growth fund invests in later-stage companies that are either generating revenue in growth rounds, pre-IPO rounds, or in pivotal clinical trials. The growth fund’s initial investments are typically in the range of $10-30 million.

The firm invests broadly in healthtech and life sciences, including therapeutics, medical devices, diagnostics, and digital health companies that address areas of unmet need. The firm has a strong interest in personalized, preventive, and precision medicine technologies and those that could improve access to care, quality of care, and cost of care.

The growth fund pursues investments in companies that are advancing the multi-omics revolution, personalizing medicine, expanding next-generation gene/cell therapy, engineering biology, and digitizing diagnostics. In Biotech and Medtech they get excited by companies that have achieved initial clinical proof of concept and can reach a significant efficacy readout over the next two years. In life science tools and diagnostics, they look for companies that have developed breakthrough instruments that are approaching or in the midst of beta testing and will begin commercialization shortly. In digital health they seek out companies that have achieved initial repeat revenues and are looking to scale commercially. At the early stage fund, they don’t define themselves by vertical, need, or even geographical boundaries but searching for transformational solutions to healthier lives and accelerated paths for value creation and building world-leading companies.

The firm seeks out great management teams that are smart problems solvers. The firm likes great technologies, but what really moves them is evidence of a highly compelling product-market fit. Market size is a consideration, but the firm cares much more about the ability to gain market access. More than momentary valuation, the firm focuses on the value that can be created by answering an unmet medical need.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a private life science investment firm with a presence in London, New York, Boston, Toronto and San Francisco. The firm looks to make investments into privately held companies and while the firm can be flexible in terms of allocation size, most investments fall in the $.5-$3million range. The firm is open to investing in companies located around the globe.

The firm is currently looking for therapeutics companies across all indication areas with particular attention to metabolic diseases (including type II diabetes), immune-oncology, aging, and infectious diseases. The firm is interested in pre-clinical stage companies that have a lead asset established as well as companies in early clinical trials. The firm is open to all molecule types that meet this criteria. The firm is generally not interested in next generation cytotoxic chemotherapies, therapies for Alzheimer’s Disease, or therapies for cardiovascular indications.

The firm is a hands-on investor which contributes substantially to the operation of their portfolio companies, often supplementing management with a network of drug developers and specialists in regulatory affairs, clinical affairs, manufacturing, and other subspecialties.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A venture capital firm located in New York City focuses on the life science industrials and invests in companies that develop tools, technologies, and services for discovery, development, and manufacturing of biologics and related therapies. The firm is focused on early-stage venture and growth equity investments. Typical equity investments range from $500k-$5 million. The firm has $65M AUM, 7 active portfolio companies to date, and is open to either leading or co-leading in a financing round.

Within life sciences, the firm is specifically focused on life science industrials: the tools, technologies, and services that enable the discovery, development, and manufacturing of life-saving therapies. The firm does not invest in therapeutics or medical devices. The firm considers Seed to Series B stage

The firm with entrepreneurs and their teams to overcome inflection points in growth. The firm takes a hands-on approach to work with its portfolio companies through focused operational and commercial guidance and an engaged approach to supporting entrepreneurial ventures.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Founded 2013, a venture capital firm is headquartered in San Francisco. The firm is investing from its most recent fund, which closed in early 2020 at $50 M. The firm invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.

The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.

The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A Toronto based venture capital firm founded in 2016 is investing out of its second fund, which was initially closed in October 2020 at USD 150 million. Among the 150 million, the firm manages to invest 100 million directly in companies while the other 50 million will invest in funds. The firm focuses on investments in three main sectors: Biopharmaceutical, Healthcare Platform & Services, and Technology (i.e., SAAS, Fintech). The firm provides initial investments at USD 3-5 million, and it will also reserve a further amount for follow-on financing and supports the startups in strategic partnerships. The firm is interested in pre-clinical to clinical-stage biotech companies. The firm invests primarily in North America but also opens to invest in Europe or China.

The firm is looking for new opportunities in the life science space, including therapeutics, diagnostics, and healthcare platforms. The firm’s investments to date have included companies developing in cell therapy, oncology, neuroscience, and drug-discovery platform. The firm is opportunistic in terms of sector, subsectors, and indications. The firm will also consider orphan drugs. Within medical devices and digital health, the firm will only consider companies that already have a USD 10 million minimum revenue. The firm will only co-invest and will prefer to co-invest with well-known lead investors.

The firm does not have specific requirements on companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.